LEVOCARNITINE SF
Clinical safety rating: safe
Animal studies have demonstrated safety
L-carnitine is a quaternary ammonium compound essential for mitochondrial transport of long-chain fatty acids for beta-oxidation. It binds to fatty acyl-CoA to form acylcarnitine, which is shuttled across the inner mitochondrial membrane by carnitine palmitoyltransferase I (CPT I) and carnitine-acylcarnitine translocase (CACT), then reconverted to acyl-CoA by CPT II for energy production.
| Metabolism | Levocarnitine is not metabolized; it is eliminated primarily by the kidneys via glomerular filtration. A small amount undergoes reversible acetylation to acetylcarnitine. |
| Excretion | Renal: 80-90% as unchanged drug via tubular reabsorption; fecal: <10%. |
| Half-life | Terminal half-life: 17.4 hours in healthy adults; prolonged in renal impairment (up to 33 hours in end-stage renal disease). |
| Protein binding | 0% (not significantly protein bound). |
| Volume of Distribution | 0.2-0.3 L/kg; distributes into skeletal muscle, heart, and liver. |
| Bioavailability | Oral: 14-18% (due to high first-pass metabolism); IV: 100%. |
| Onset of Action | Oral: 1-2 hours (peak plasma levels at 3-6 hours); IV: immediate. |
| Duration of Action | Oral: 12-24 hours (sustained by renal reabsorption); IV: 6-12 hours depending on dose. |
990 mg orally twice daily, adjusted based on serum carnitine levels.
| Dosage form | SOLUTION |
| Renal impairment | For GFR <30 mL/min, reduce dose by 50% and monitor levels. |
| Liver impairment | No specific dose adjustment defined for hepatic impairment; use caution in severe disease. |
| Pediatric use | 50-100 mg/kg/day orally divided into 2-3 doses, not to exceed 3 g/day. |
| Geriatric use | Start at lower end of adult dosing; monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause nausea and vomiting.
| Breastfeeding | Levocarnitine is naturally present in breast milk; concentrations are influenced by maternal levels. Limited data on exogenous levocarnitine in lactation. M/P ratio not established for supplemental dosing. Generally considered compatible with breastfeeding at recommended doses as it is an endogenous substance. Monitor infant for potential gastrointestinal effects. |
| Teratogenic Risk | Teratogenic risk profile for LEVOCARNITINE SF is not well-established in human pregnancy. Animal studies have not shown teratogenic effects at clinically relevant doses. First trimester: No known risk, but data insufficient to exclude risk. Second and third trimesters: No known adverse fetal effects, but monitor for potential maternal carnitine deficiency or excess. Overall, classified as FDA Pregnancy Category B (if applicable) — no evidence of risk in humans based on animal data. |
■ FDA Black Box Warning
None.
| Common Effects | Nausea |
| Serious Effects |
["Hypersensitivity to levocarnitine or any component of the formulation"]
| Precautions | ["Seizures: Rarely, seizures have been reported, especially in patients with pre-existing seizure disorder.","Renal impairment: Accumulation can occur in patients with severe renal dysfunction; adjust dose or avoid.","Gastrointestinal symptoms: Nausea, vomiting, diarrhea, and abdominal cramps can occur.","Body odor: Can produce a fishy odor due to trimethylamine production.","Hypoprothrombinemia: Monitor prothrombin time in patients on anticoagulants."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum carnitine levels periodically to avoid toxicity or deficiency. Assess for signs of hyperammonemia (e.g., lethargy, vomiting) in both mother and fetus/neonate. During pregnancy, monitor fetal growth and well-being via ultrasound and antenatal testing. In neonates, check for metabolic acidosis and hyperammonemia if mother is on high doses. |
| Fertility Effects | No known adverse effects on fertility. Levocarnitine is essential for energy metabolism; deficiency may impair sperm function and ovulation. Supplementation may improve fertility in individuals with carnitine deficiency. No negative impact on fertility reported at therapeutic doses. |